Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II study of QL2401 injection in MASH with F2-F3 liver fibrosis
CTR20262113Phase 2Active
- Sponsor
- Qilu Pharmaceutical
- Start
- Jun 2026
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of QL2401, sponsored by Qilu Pharmaceutical. Started Jun 2026; status: active.
02
Drugs
QL2401
Beyond the preview
Go deeper on CTR20262113.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20262113.